Benjamin L. Palleiko - Nov 11, 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Benjamin L. Palleiko
Stock symbol
KALV
Transactions as of
Nov 11, 2025
Transactions value $
-$38,438
Form type
4
Date filed
11/13/2025, 04:28 PM
Previous filing
Sep 9, 2025
Next filing
Nov 19, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Palleiko Benjamin L CHIEF EXECUTIVE OFFICER, Director C/O KALVISTA PHARMACEUTICALS, INC., 200 CROSSING BOULEVARD, FRAMINGHAM /s/ Benjamin L. Palleiko 2025-11-13 0001366244

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise +7.12K +1.8% 402K Nov 11, 2025 Direct F1
transaction KALV Common Stock Sale -$38.4K -3.33K -0.83% $11.55 399K Nov 12, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Options Exercise $0 -7.12K -6.25% $0.00 107K Nov 11, 2025 Common Stock 7.12K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 11, 2025, subject to continued service through each vesting date.